Daniel Zaharevitz - Concepedia

Author

Daniel Zaharevitz

Also Known As

D W Zaharevitz, D Zaharevitz, D. W. Zaharevitz, D. W., Zaharevitz, D. ZAHAREVITZ, D. Zaharevitz, DANIEL ZAHAREVITZ, Daniel W Zaharevitz, Daniel W. ZAHAREVITZ, Daniel W. Zaharevitz

Publications

6.4K

Citations

H-Index

101

Concepts

All Affiliations

National Cancer Institute National Institutes of Health Universität Hamburg Science Applications International Corporation (United States)Station Biologique de Roscoff

About

Daniel Zaharevitz is an author at National Cancer Institute specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	31	2.7K
2	Biochemistry	13	14	981
3	Natural Sciences	12	12	1.5K
4	Engineering	2	2	37
5	Health Sciences	2	2	283

Daniel Zaharevitz

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
An Information-Intensive Approach to the Molecular Pharmacology of Cancer John N. Weinstein, Timothy G. Myers, P M O'Connor, Science	1997	1.2K
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials J I Johnson, Shannon Decker, Daniel Zaharevitz, British Journal of Cancer	2001	850
A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells Paraskevi Giannakakou, Rick Gussio, Eva Nogales, Proceedings of the National Academy of Sciences Tubulin BindingDrug TargetMolecular BiologyTubulin Mutant CellsChemical Biology	2000	475
Paullones are potent inhibitors of glycogen synthase kinase‐3β and cyclin‐dependent kinase 5/p25 Maryse Leost, Christiane Schultz, Andreas Link, European Journal of Biochemistry	2000	370
Paullones, a Series of Cyclin-Dependent Kinase Inhibitors: Synthesis, Evaluation of CDK1/Cyclin B Inhibition, and in Vitro Antitumor Activity Christiane Schultz, Andreas Link, Maryse Leost, Journal of Medicinal Chemistry	1999	326
A Common Pharmacophore for a Diverse Set of Colchicine Site Inhibitors Using a Structure-Based Approach Tam Luong Nguyen, Connor F. McGrath, Ann Hermone, Journal of Medicinal Chemistry Drug TargetProtein AssemblyMolecular BiologyColchicine SitePharmacotherapy	2005	286
Models for Evaluating Agents Intended for the Prophylaxis, Mitigation and Treatment of Radiation Injuries Report of an NCI Workshop, December 3–4, 2003 Helen B. Stone, John E. Moulder, C. Norman Coleman, Radiation Research December 3–4Radiation EffectRadiation ExposureSurgeryInjury Prevention	2004	241
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Daniel Zaharevitz, Rick Gussio, Maryse Leost, PubMed Drug TargetChemoprevention StrategyPathologyPharmacotherapyTumor Biology	1999	226
Identification of a Potent and Selective Pharmacophore for Cdc25 Dual Specificity Phosphatase Inhibitors. John S. Lazo, Kaoru Nemoto, Katharine Pestell, Molecular Pharmacology	2002	182
Chemical synthesis and biological properties of pyridine epothilones K. C. Nicolaou, Rita Scarpelli, Birgit Bollbuck, Chemistry & Biology	2000	144

Page 1